| Literature DB >> 1782071 |
F J van Breukelen1, K Mattson, G Giaccone, N van Zandwijk, H T Planteydt, A Kirkpatrick, O Dalesio.
Abstract
46 patients with malignant pleural mesothelioma were entered in a phase II study of mitoxantrone 14 mg/m2 every 3 weeks. Histology was confirmed by a pathology panel. None of the patients had received previous chemotherapy. Toxicity was mainly mild gastrointestinal and haematological side-effects. Out of 34 patients evaluated for response, only 1 partial response was recorded. Mitoxantrone at this dose and schedule has marginal activity in malignant mesothelioma.Entities:
Mesh：
Substances：
Year: 1991 PMID： 1782071 DOI： 10.1016/0277-5379(91)90430-l
Source DB: PubMed Journal: Eur J Cancer ISSN： 0959-8049 Impact factor: 9.162